Silver Book

Silver Book Fact

Treatment of patients with advanced dry age-related macular degeneration (AMD) with ciliary neurotrophic factor (CNTF) implants resulted in stabilization of visual acuity.  A sub-group analysis found that 100% of patients receiving a high-dose lost <15 letters of acuity–compared with 55.6% in the combined low-dose/sham group.  The high-dose group had a 0.6 mean letter gain while the low-dose/sham group had a mean 9.7 letter loss.

Zhang K, Hopkins J, Heier J, Birch D, et al. Ciliary Neurotrophic Factor Delievered by Encapsulated Cell Intraocular Implants for Treatment of Geographic Atrophy in Age-Related Macular Degeneration. PNAS. 2011; 108(15). http://www.pnas.org/content/early/2011/03/24/1018987108

Reference

Title
Ciliary Neurotrophic Factor Delievered by Encapsulated Cell Intraocular Implants for Treatment of Geographic Atrophy in Age-Related Macular Degeneration
Publication
PNAS
Publication Date
2011
Authors
Zhang K, Hopkins J, Heier J, Birch D, et al
Volume & Issue
Volume 108, Issue 15
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Of the 8 Million older Americans at high risk of developing advanced age-related macular degeneration (AMD), 1.3 million will develop advanced AMD within 5 years.  However the NEI-sponsored Age-Related Eye…  
  • Laser Treatment for DR
    Laser treatment of PDR can reduce the 5-year risk of blindness by 90%, and the risk of visual loss from DME by 50%.  
  • DR Treatment Savings in the US
    Every year, the U.S. saves an estimated $1.6 billion by treating DR.  
  • Treatment of patients with advanced dry age-related macular degeneration (AMD) with ciliary neurotrophic factor (CNTF) implants resulted in stabilization of visual acuity.  A sub-group analysis found that 100% of patients…  
  • A study on the impact of diet on age-related macular degeneration (AMD) found that those who took the highest amounts of carotenoids, such as lutein and zeaxanthin, had a 43%…